Secondary Lymphoid Organs in Mesenchymal Stromal Cell Therapy: More Than Just a Filter

Di Zheng¹, Tejasvini Bhuvan¹, Natalie L. Payne¹,² and Tracy S. P. Heng¹,³*

¹ Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia, ² Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia, ³ ARC Training Centre for Cell and Tissue Engineering Technologies, Monash University, Clayton, VIC, Australia

Mesenchymal stromal cells (MSCs) have demonstrated therapeutic potential in inflammatory models of human disease. However, clinical translation has fallen short of expectations, with many trials failing to meet primary endpoints. Failure to fully understand their mechanisms of action is a key factor contributing to the lack of successful commercialisation. Indeed, it remains unclear how the long-ranging immunomodulatory effects of MSCs can be attributed to their secretome, when MSCs undergo apoptosis in the lung shortly after intravenous infusion. Their apoptotic fate suggests that efficacy is not based solely on their viable properties, but also on the immune response to dying MSCs. The secondary lymphoid organs (SLOs) orchestrate immune responses and play a key role in immune regulation. In this review, we will discuss how apoptotic cells can modify immune responses and highlight the importance of MSC-immune cell interactions in SLOs for therapeutic outcomes.

Keywords: mesenchymal stromal cells, cell therapy, immune responses, apoptosis, secondary lymphoid organs, spleen, lymph nodes, efferocytosis

INTRODUCTION

Mesenchymal stem cells, more accurately known as mesenchymal stromal cells (MSCs), are one of the most widely investigated therapeutic cell types, owing to their ease of accessibility and expansion from tissues free of ethical concerns, as well as their immunomodulatory capacity in various preclinical disease models (1–3). MSCs can be sourced from the stroma of almost all tissues, but most commonly from bone marrow (BM), adipose tissue (AD) and umbilical cord (UC) (4, 5). MSCs are contained within a heterogeneous population expressing CD105, CD73 and CD90 while lacking CD45, CD11b, CD19 and HLA-DR. They are characterized by their adherence to plastic and ability to differentiate into osteoblasts, adipocytes and chondrocytes in vitro (6).

With increasing clinical translation, however, this minimal set of criteria is now recognized as inadequate for defining MSCs. It does not reflect MSC potency, which is largely based on broad immunomodulatory properties (7), rather than their self-renewal or multipotential capacity (8, 9). It does not address changes in marker expression levels or biological properties due to culture expansion and cell manufacturing processes (10), including cryopreservation and freeze-thawing (11). Additionally, it does not identify the risk profile of the MSC product, particularly with regard to hemocompatibility of intravenously (IV) delivered cells and their potential to trigger adverse thromboembolic events (12). Thus, proposed amendments to the criteria have included functional...
potency assays based on the immunomodulatory activity of MSCs (13), and profiling of the hemocompatibility of the diverse array of MSC products now in clinical use (14).

The preclinical efficacy of MSCs in various unrelated conditions such as graft-versus-host disease (GvHD), Crohn’s disease, kidney transplantation, myocardial infarction, stroke, diabetes, acute respiratory distress syndrome (ARDS), multiple sclerosis, and brain and spinal cord injury, mainly relates to immune regulation (15–20). In vitro studies have shown that MSCs can modulate adaptive and innate immune responses. MSCs suppress T cell proliferation, cytokine response (e.g. IFN-γ production) and cytotoxic activity in response to antigen-specific stimuli (21–23) whilst promoting regulatory T cells (Tregs), via their production of soluble factors (Figure 1) such as nitric oxide (NO), indolamine 2,3 dioxygenase (IDO) and transforming growth factor-beta (TGF-β) (24, 30–32). MSCs can also downregulate the cytokine responses of innate immune cells, including dendritic cells (DCs) and monocytes, via the expression of prostaglandin E2 (PGE2) (33). How these in vitro findings relate to their mode of action remains to be clarified, given the complexity of immune responses in vivo and the short persistence of MSCs following infusion.

MSC SURVIVAL AND BIODISTRIBUTION

To date, studies have investigated different routes of MSC administration in order to maximise therapeutic efficacy. The different administration routes result in variations in MSC survival. IV infusion has been the most commonly used and studied method for MSC delivery because it is convenient, minimally invasive and reproducible (4). However, MSCs administered via the IV route are entrapped in the lung and rapidly cleared, with few traces detected in other tissues (34, 35). Studies using various MSC detection techniques, including MSCs constitutively expressing fluorescent proteins or luciferase, or labelled with fluorescent dyes or radioactive tracers, showed that viable MSCs are detected in the lung within 24 hours of IV administration but not at 72 hours (35–37). The decrease in detectable viable cells is directly proportional to the increase in dead cells in the lungs, indicating that IV-infused MSCs undergo cell death (37). Activation of caspase 3, a hallmark of apoptosis, in MSCs further indicates that MSCs undergo programmed cell death following their entrapment in the lung (38, 39).

The survival of IV-delivered MSCs can also be compromised if cells trigger the instant blood-mediated inflammatory reaction (IBMIR) due to incompatibility with blood (40). Expression of secreted and cell surface immunogenic factors (e.g. tissue factor (TF)/CD142) vary across MSC tissue sources and cell manufacturing conditions, including freeze-thawing and culture passaging (12, 14). These factors can activate the innate immune system and trigger the coagulation and complement cascades, which limit MSC engraftment and efficacy, but also increase the potential for adverse thromboembolic events (41).

Other injection routes, including intraperitoneal (IP), subcutaneous (SC), and intramuscular (IM), which bypass the lung, have also been examined. Prolonged detection of MSCs has been observed following IP and SC injection (42, 43). Following IM injection, a dwell time of up to 5-month was observed (44). Other studies have administrated MSCs directly into the diseased tissue, for example, intratracheal administration in models of lung inflammation or intrathecal administration in models of spinal cord injury or neuroinflammatory disease (45–48). In these studies, MSCs are directly exposed to an inflammatory

![FIGURE 1](https://www.frontiersin.org) | Immunomodulatory capacity of viable and apoptotic MSCs. (A) Live or viable MSCs can sense the microenvironment and respond to cytokine signals by polarizing into ‘pro-inflammatory’ or ‘anti-inflammatory’ phenotypes (24). ‘Anti-inflammatory’ MSCs produce anti-inflammatory soluble factors, including IDO and TGF-β, to modulate immune cell function and dampen inflammation. MSCs also produce extracellular vesicles (EV), such as exosomes, that can be immunomodulatory, depending on their cargo (19, 25). (B) Excessive inflammatory stress or the presence of cytotoxic immune cells will induce apoptosis of MSCs (28). MSCs can undergo a pre-apoptotic stage, known as autophagy. Autophagic MSCs, as well as the EVs produced during this stage, may have roles in immunosuppression (27). (C) As MSCs undergo apoptosis, their apoptotic secretome can promote an anti-inflammatory microenvironment and attract phagocytes for effectorcytosis (28). Phagocytes that have engulfed the apoptotic MSCs become immunomodulatory and have downstream regulatory effects on adaptive immune cells, such as T cells (29). Figure was created with BioRender.com.
environment, which can influence MSCs survival and therapeutic efficacy (26, 49). Pre-conditioning of MSCs via hypoxia or serum deprivation for instance, can promote cell survival when subsequently exposed to an ischemic environment (50–52). Although the quantity, duration and the type of stress insult matter, overall, excessive stress will likely predispose MSCs to cell death (26).

In some disease settings, dead or dying MSCs and their associated ‘by-products’ can contribute to therapeutic efficacy (38, 39, 53–55) raising additional questions about their mode of action. How are MSCs killed in different microenvironments? How does the dying process contribute to therapeutic efficacy in different disease settings? Importantly, how do IV administered MSCs dying in the lung exert anti-inflammatory effects in distal organs in disease settings that seemingly do not involve the lung?

**MSC APOPTOSIS AND THEIR IMMUNOSUPPRESSIVE ‘BY-PRODUCTS’**

The molecular pathway that induces the death of MSCs in vivo is unclear and complicated by pre-existing disease, inflammatory cell infiltrate and the presence of different pathogens (26). The stress signals from the inflammatory microenvironment can trigger the apoptosis of MSCs. In a mouse model of GvHD, the presence of elevated numbers of cytotoxic CD8+ T cells and CD56+ natural killer (NK) cells in the lung caused MSC apoptosis (38). Settings that do not involve cytotoxic cell infiltrate likely involve other mechanisms. We recently showed that disabling the intrinsic (mitochondrial) pathway of apoptosis in MSCs prevented caspase 3 activation in the lung shortly after IV injection, indicating that MSCs were predominantly killed via the intrinsic pathway in non-GvHD settings (39). Activation of coagulation and complement by infused MSCs has also been shown to damage and reduce viability of MSCs (40, 56). Stronger activation of these proteolytic cascades is demonstrated by freeze-thawed (without culture recovery) and high-passage MSCs compared with fresh culture-derived, minimally expanded cells. This is due to variations in expression of immunogenic triggers, which may subsequently impact their in vivo therapeutic function (11).

In general, apoptosis is an ordered event that creates a transient immunosuppressive microenvironment via the release of anti-inflammatory mediators, including IL-10, TGF-β, CCR5, annexin-A1 and thrombospondin-1 (Figure 1) (28). Besides these secreted factors, cells can undergo a pre-apoptotic stage known as autophagy when they sense danger or stress signals from the microenvironment (57). By culturing MSCs in a stressed environment, autophagic MSCs can be pre-engineered to secrete immunomodulatory factors, such as TGF-β, to regulate T cell proliferation (58). Interestingly, MSCs have been shown to communicate with damaged cells via bidirectional transfer of mitochondria to increase mitochondrial biogenesis and rescue the cellular function of damaged cells (27). In preclinical models of myocardial infarction and respiratory disorders, mitochondrial transfer has been shown to contribute to the therapeutic effects of MSCs (Figure 1) (27, 59–61). MSCs can transfer mitochondria via tunnelling nanotubules, cell fusion or extracellular vesicles (EV), which influence the macrophage function to modulate inflammation (59, 62). Whilst mitochondrial transfer has yet to be demonstrated in apoptotic MSCs, apoptotic bodies, which are a distinct type of extracellular vesicles formed when apoptotic cells disassemble into fragments (63), may also contribute to therapeutic efficacy upon engulfment by macrophages (64). Thus, MSCs are susceptible to cell death post-administration, which contributes to the anti-inflammatory effects of MSC therapy (10, 39).

**EFFEROCYTOSIS OF MSCs**

Rapid clearance of apoptotic debris by phagocytes is essential in maintaining body homeostasis. Known as efferocytosis, this physiological process ‘silently’ removes apoptotic cells, inducing peripheral tolerance and avoiding inflammation. Phagocytic cells, including macrophages and monocytes, play a critical role in MSC therapy, as demonstrated in disease models where depletion of macrophages with clodronate liposomes renders MSC therapy ineffective (33, 36, 38). Phagocytes that have engulfed apoptotic cells, including MSCs, display a regulatory phenotype characterized by upregulation of PD-L1, IDO, COX2 and CD206, increased production of IL-6, IL-10, TGF-β and PGE2, and decreased production of pro-inflammatory cytokines such as TNF-α and IL-12 (29, 37, 65). Phagocytes that have engulfed apoptotic MSCs can suppress T cell proliferation, downregulate CD4+ T cell activation and promote Foxp3+ Treg generation (29, 37). The inhibition of COX2 abrogated the immunosuppressive capacity of effector monocytes that had engulfed apoptotic MSCs, highlighting the importance of the PGE2/COX2 axis in this immunosuppressive function (29).

Since MSC apoptosis and the subsequent response of immune cells to this process contributes to their immunomodulatory effects, an outstanding question is whether viable MSCs are still required for MSC therapy, or can pre-inactivated MSCs be used as an alternative?

**APOPTOTIC OR DEAD MSCs AS A THERAPEUTIC CELL OPTION**

Several studies have investigated the efficacy of in vitro induced apoptotic, dead or inactivated MSCs. Treatment outcomes can be influenced by the type and duration of stimulation used to inactivate the cells, and also the disease setting (26). Apoptotic MSCs (39, 53, 54), but not dead MSCs (36, 66) could inhibit lung inflammation. In certain disease settings, such as LPS-induced sepsis, inactivated or dead MSCs could replicate the immunomodulatory effects, as pre-inactivation enhanced the phagocytosis of MSCs (55, 67). In other settings, non-viable MSCs were ineffective or did not fully replicate the effects of...
viable MSCs (33, 42, 67). For instance, in GvHD, apoptotic MSCs had to be administered at a much higher dose than viable MSCs to achieve comparable therapeutic benefits (38). It is plausible that inflammatory diseases driven by innate immune or phagocytic cells are more likely to benefit from treatment with inactivated MSCs, while suppression of T cell responses require MSCs with an active secretome (67). Importantly, the type and stage of cell death at the time of MSC administration are key considerations, as apoptosis, but not necrosis or lytic cell death, induces anti-inflammatory responses (68).

Although MSC apoptosis and the subsequent host phagocytic response contribute to immunomodulation, there remains much to learn about the full mechanisms of MSC therapy. As MSC apoptosis and efferocytosis occurs in the lung post-infusion, how does this dampen inflammation in other organs or tissues? In vitro studies have shown that MSCs can regulate immune cell function via their paracrine activity, but such molecules must have a relatively long half-life and broad biodistribution for this to be a plausible mechanism in vivo. Immune responses are initiated and maintained in the SLOs, which play a key role in immune regulation during health and disease. Thus, our knowledge of how MSC therapy modulates immune responses would be improved by considering the known function of SLOs, their role in clearance of apoptotic cells and gaining a better understanding of the effects of MSCs in these organs.

ORGANIZATION AND FUNCTION OF SECONDARY LYMPHOID ORGANS

Primary lymphoid organs, also known as central lymphoid organs, are the sites for the development and maturation of leukocytes. Primary lymphoid organs include the bone marrow and thymus (69–71). Lymphocytes (a class of leukocytes, e.g. T and B cells) generated in primary lymphoid organs then seed the SLOs where they initiate adaptive immune responses. SLOs include lymph nodes (LNs), spleen, tonsils, adenoids, Peyer’s patches, and mucosal-associated lymphoid tissues (MALT) (71). The localisation of lymphocytes in SLOs maximizes their interaction with foreign antigens that drain to the SLOs via blood or lymphatics. Antigen presenting cells, such as DCs, can also transport antigens to SLOs and activate lymphocytes there. Once activated, these lymphocytes undergo expansion and differentiate into effector or memory cells to provide antigen-specific responses. This review will focus on the spleen and LNs as the major SLOs.

Structure and Function of the Spleen

The spleen is a network of branching arterial vessels that functions to filter blood, allowing for the capture of blood-borne pathogens and antigens, and is a key organ for iron metabolism and erythrocyte homeostasis (72, 73). Although early research suggested that excision of the spleen does not largely impact the human immune system, its functional significance has been demonstrated through various studies over the years. While the human and mouse spleen is similar in terms of gross structure and immune cell function, some key differences are known to exist and have been reported elsewhere (73–75). This section will focus on the mouse spleen.

The spleen is composed of the white pulp (WP) and red pulp (RP), with the marginal zone (MZ) situated in between (76, 77), (Figure 2). Arterial blood arrives at the MZ and runs through the cords in the RP, where the F4/80+ RP macrophages (RPMs) monitor and phagocytose incoming aged erythrocytes (85, 86). In addition, RPMs also extract any dead or opsonized cells from the circulation, while simultaneously surveying for pathogens and tissue damage (78). Other leukocyte populations located in the RP, including neutrophils, monocytes and γδ T cells, exert immune effector functions upon encountering an inflammatory insult (72, 76, 77). Blood is recollected in sinuses to form the venous sinusoidal system and ultimately enters the efferent vein for return to the systemic circulation (77, 79, 80).

The white pulp is the site of lymphocyte differentiation and initiation of immune responses to blood borne antigens. Correct organization and maintenance of the WP is regulated by specific chemokines that attract T cells and B cells and establish their respective zones within the WP (81, 82). The continuous traffic of haematopoietic cells in and out of the spleen is an efficient way for these cells to survey the blood for pathogens and antigens.

The MZ is an important transit area for cells that are leaving the bloodstream and entering the WP. It contains a number of resident cells that have unique properties, including a subset of DCs and innate-like B cells called MZB cells (73, 84). Two specific subsets of macrophages are also found here: MZ macrophages (MZMs) and marginal metallophilic macrophages (MMMs) (76, 87). The MZMs line the outer ring of the WP and are characterized by expression of C-type lectin SIGNR1 and type I scavenger receptor MARCO (85, 88). The MMMs form the inner ring, located closer to the WP (89, 90). These macrophages are characterized by expression of the adhesion molecule SIGLEC1 (CD169) (82, 91–93).

Structure and Function of the Lymph Node

While the spleen filters the blood and protects the host against blood-borne pathogens, LNs bring antigens draining from tissues together with lymphocytes circulating in the blood. There are more than 20 identified lymph nodes in mice and over 500 in humans, located at multiple sites throughout the lymphatic circulatory system (94, 95). Current understanding of LN structure and function is mainly gained from animal studies.

The parenchyma of the LN is compartmentalized by stromal cells and organized into the cortex at the outermost region containing B cell follicles, the paracortex in the inner region containing the T cell zone, and the medulla proximal to the efferent lymphatic vessels containing the medullary sinuses (95, 96). (Figure 3). Lymphocytes in the blood enter the LNs via high endothelial venules (HEVs) directly into the paracortex area. Lymph, containing soluble and cell-associated antigens, enters the LNs via afferent lymphatic vessels and is filtered through the lymphatic sinus (71, 95). Subcapsular sinus macrophages (SSMs) survey and capture lymph-borne antigens before they enter the
cortex and paracortex, acting as gatekeepers that protect the host from aberrant immune responses and preventing the systemic spread of antigens (97–99, 102, 103). SSMs initiate innate immune responses by producing pro-inflammatory cytokines to recruit innate immune cells, and can also activate adaptive immunity by extending across the subcapsular sinus floor to present antigen to B cells in the follicles (99, 104).

Lymph passing by the subcapsular sinus will encounter another type of sinus macrophage, known as medullary sinus macrophages (MSMs). MSMs are located along the sinus of the medulla region, interacting with the lymph and also lymphocytes that are egressing the LN (97). Functionally, MSMs can actively phagocytose antigens, as well as apoptotic immune cells in the lymph (105–107). As the lymph passes through the medullary sinus, it then exits the LNs via the efferent lymphatic vessel and eventually return to the blood circulation.

The LN contains other macrophages that are also important in maintaining tissue homeostasis and clearing apoptotic debris. Medullary cord macrophages (MCMs) support plasma cell survival and efferocytosis apoptotic debris, while tingible body macrophages (TBMs) are involved in the clearance of apoptotic B cells in the germinal centre (97). A recent study has identified a resident macrophage population in the T cell zone, known as T cell zone macrophages (TZMs), that efferocytose apoptotic DCs draining from the periphery (100). As efferocytosis induces an immunomodulatory phenotype in phagocytes, these LN resident macrophages play an important role in immune regulation.

**APOPTOTIC CELL CLEARANCE AND TOLERANCE IN SLOs**

Essentially all tissues undergo programmed cell death, known as apoptosis, evident through the constant turnover of cells. Under homeostatic conditions, apoptotic cells rarely accumulate in tissues due to the efficient efferocytosis by tissue phagocytes. The clearance of apoptotic cells is linked to an anti-inflammatory response that also induces immunological tolerance (108, 109). The precise apoptotic cell machinery and phagocytic components involved in apoptotic cell-induced immunosuppression are reviewed extensively elsewhere (109–112). However, it is clear that the efficient clearance of apoptotic cells can be attributed to the redundancy in the mechanisms of apoptotic cell recognition.

Splenic and LN macrophages are known to participate in the efferocytosis of apoptotic cells and maintenance of immune tolerance. TZMs and TBMs in the LN are known to engulf apoptotic debris silently without stimulating T cells, in order to maintain local immune homeostasis (100). The splenic MZ is also involved in the clearance of apoptotic cells from the circulation. IV-injected apoptotic cells drain to the splenic MZ, where they are rapidly engulfed by macrophages in the marginal zone (83). MZMs are known to be critical for particulate trapping in the spleen (72). Depletion studies (in which both MZMs and MMMs are depleted) have also indicated a crucial role for MZ macrophages in apoptotic cell-driven immunomodulation. The initial engulfment of apoptotic cells by macrophages in the MZ is...
vital in the generation of tolerance to self, whereby delayed clearance of apoptotic cells results in reduced immune tolerance to apoptotic cell-associated antigens (113). For example, depletion of MZ macrophages led to development of systemic tolerance breakdown in mouse models of systemic lupus erythematosus (SLE) and induced inflammatory responses towards apoptotic cell antigens (113).

The infusion of apoptotic cells has been reported to induce immunosuppression in experimental inflammatory diseases, autoimmunity and transplantation. In animal models of autoimmune arthritis, when apoptotic cells were infused not at the joint, but via the IV (114–116) or IP route (114, 117), the resolution of arthritic inflammation was conserved at the joint. In mouse models of transplantation, IV infusion of donor apoptotic splenocytes was shown to promote donor-specific immunosuppression, prolonging the survival of heart allografts (118, 119). Clinical studies have also shown that infusion of leukocytes rendered non-viable, either via a chemical cross-linker, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (ECDI) or extracorporeal photochemotherapy, is safe and potentially beneficial in multiple sclerosis (120) and cutaneous T cell lymphoma (121). In apoptotic cell-based therapies, the spleen plays a pivotal role as splenic macrophages and DCs are involved in the phagocytosis of apoptotic leukocytes administrated via the IV route (122, 123). Together, these findings point to a critical role for the SLOs in the clearance of apoptotic cells and establishment of a tolerogenic state.

**SLOs IN DISEASE**

SLOs have a crucial role in host immune defense. In SLOs, antigen priming and immune cell activation occurs, followed by clonal expansion of antigen-specific effector lymphocytes, and the formation of immunological memory and tolerance. The importance of the spleen in host immunity has been demonstrated in various disease settings. In a long-term follow-up study, patients whose spleen had been surgically removed had an increased risk of developing bacterial infections (124). In malaria, the spleen is important in controlling the blood stage infection, clearance of parasitized red blood cells, induction of memory lymphocytes and replenishment of healthy red blood cells (125, 126). Splenectomized patients infected with malaria experienced enhanced parasitic burden, severe disease symptoms, and higher mortality rate (126).

Although SLOs are protective during infection, they may also promote the establishment and progression of some inflammatory diseases. LNs are the key sites for the initiation of GvHD and acute colitis (127, 128). In GvHD, donor cells migrate to the recipient LNs via their expression of lymphoid homing molecules, CD62L (L-selectin) and CCR7 (C-C chemokine receptor 7) (129). Upon recognition of alloantigen on the donor cells, T cells in the recipient LNs are activated and migrate to tissues where they cause damage (commonly in skin, gut and liver) (127). In acute colitis, intestinal migratory DCs
drain to the mesenteric LNs where they present antigen and induce Th1 or Th17 responses (128, 130, 131). Pathogenic Th17 cells can also migrate from the mesenteric LNs to the gut and cause inflammatory bowel disease (131). Some studies have shown that lymphadenectomy (surgical removal of a group of lymph nodes and surrounding lymphatic tissues) protected rats from GvHD (132, 133). Lymphadenectomy is rarely investigated in clinical studies for the purpose of reducing inflammation, although it is performed on cancer patients to stop the spread of tumor metastases via the lymphatic system, or to remove the tumor cells in the lymphatic tissues (134, 135).

The spleen can also promote inflammatory responses in some disease settings. For example, splenectomy showed protective effects (e.g. reduced infarct volume) in rat models of brain, liver, kidney and intestine ischemic injury (136–140). In animal models of ischemic brain injury and also in patients with stroke, spleen atrophy (reduction in splenic weight and size) is commonly observed and thought to be a result of splenic leukocytes egressing via the blood circulation and into the injured brain (141). These circulating leukocytes are composed of monocytes, macrophages, neutrophils and lymphocytes, and their migration to the brain exacerbates inflammation and neurodegeneration (142, 143). Splenectomy performed on a rat stroke model (middle cerebral artery occlusion, MCAO), prior to injury, showed neuroprotective effects, with a reduction in brain infarct volume, peripheral immune cells and activated microglia in the brain infarct tissue (140, 142). Apart from the infiltration of splenic immune cells into the brain injury sites, the spleen also contributes to brain inflammation by producing pro-inflammatory signals, such as IFN-γ (140).

The involvement of SLOs and peripheral immune cells in the progression of central nervous system (CNS) inflammation has also been highlighted in other disease models, including spinal cord injury and experimental autoimmune encephalomyelitis (EAE, mouse model of multiple sclerosis) (144–146). In these disease settings, peripheral T cells and myeloid cells are recruited to the CNS and promote disease symptoms by enhancing inflammation. The crucial contribution of splenic T cells in promoting neuroinflammation is further demonstrated in neuropathic pain studies, in which the adoptive transfer of splenic T cells elevated neuropathic pain symptoms in the recipient (144).

Understanding how SLOs regulate the inflammatory response in such disease settings is important in defining the role of these SLOs in mediating the immunomodulatory effects of cell therapy.

**SLOs IN CELL THERAPY**

Given the importance of SLOs in disease progression and tolerance induction, there is emerging evidence for their involvement in cell therapy in experimental disease models. A notable example is stroke, where IV administration of different therapeutic cell types, such as umbilical cord blood cells, haematopoietic stem cells, amnion epithelial cells, bone marrow stromal cells and multipotent adult progenitor cells, were shown to induce neuroprotective effects (147–150). IV-injected therapeutic cells were detected in the spleen and induced an anti-inflammatory environment that promoted repair in the CNS (e.g. infarct size, peripheral immune cell infiltration) (149–151). Of note, a study using neural stem cells to treat stroke showed that the direct interaction between IV-administered stem cells with splenocytes, particularly CD11b+ cells, was necessary for the treatment to be neuroprotective, with splenectomy abolishing the beneficial effect (152). In line with this, the improvement in functional recovery from stroke in MAPC-treated animals was also not evident in the absence of a spleen, supporting a critical role for the spleen (153).

**MSC Biodistribution in SLOs**

Despite the central role of the spleen and lymph nodes in the blood and lymph network respectively, MSCs are rarely detected in the SLOs. When reported, the presence of MSCs in the SLOs is usually minimal and requires sensitive detection techniques (Figure 4). Small numbers of MSCs were detected in spleen and lymph nodes 24 hours post-IV infusion in naïve mice (154), and for up to 5 weeks in a mouse model of sclerodermatous GvHD (155). Similarly, localization within the spleen and LNs may also occur in the days after IP, but not SC or IM, infusion (44), although MSC biodistribution was variable following this delivery route and attachment of MSC aggregates to the peritoneal walls has been reported (157).

It is thought that the presence of MSCs in SLOs is a result of their active migration, since they express higher levels of homing molecules, including CCR7, CD62L and intercellular adhesion molecule-1 (ICAM-1), compared to other fibroblastic cells (154, 158, 159). MSCs engineered to overexpress CCR7 or ICAM-1 showed improved MSC migration to the spleen and LNs post-IV injection in a GvHD model (158, 159). The increased distribution of MSCs within SLOs correlated with an improvement in their immunomodulatory effects and clinical outcomes in these disease models (158, 159).

The presence of inflammation can influence the biodistribution of MSCs in SLOs. In a myocardial infarction (MI) model, the presence of inflammation increased the recruitment of IV-infused MSCs to the spleen compared to controls without MI (160). In contrast, inflammation can reduce the presence of MSCs in the LNs. In experimental models of colitis and delayed-type hypersensitivity (DTH) (154, 161), accumulation of MSCs was reduced in the LNs and redistributed towards the inflamed tissues. However, it is important to note the caveats of the labelling approaches used in such studies. For example, membrane dyes are retained when cells lose membrane integrity upon cell death, making it hard to discriminate signals from viable cells, cellular debris, or redistribution by phagocytes that had engulfed apoptotic cells (162). Moreover, studies have repeatedly shown that the small numbers of detectable MSCs eventually get cleared (35, 39, 163), yet their interaction with the host immune system within minutes to hours post-IV infusion is likely critical to therapeutic outcomes. For instance, complement activation by MSCs can adversely trigger IBMIR, but has also been found to
upregulate the expression of CD11b on blood myeloid cells, which mediate the immunosuppressive effects of MSCs (164). Clarification of whether the detection of MSC signals in SLOs indicates the presence of viable MSCs or apoptotic cell clearance therefore has important implications for our understanding of the mechanisms of MSC therapy.

**MSCs Regulate the T Cell Profile in SLOs**

In several disease settings, the cellular composition of SLOs and function of their immune cells are changed upon cell therapy. The presence of MSCs is also found to associate with a change in the total cellularity of the SLO (154, 158, 160, 165). In a model of myocardial infarction, MSC recruitment to the spleen was shown to decrease splenic natural killer cells and neutrophils (160). In a stroke model, the infusion of human umbilical cord blood cells altered the T cell and monocyte/macrophage composition in the spleen (165). In GvHD and DTH models, MSC recruitment to the LNs was also observed to regulate the survival and activation of lymphocytes, in particular, T cells (154, 158).

The splenic T cell profile is further modulated following cell therapy. Splenic T cells from animals that had received cell therapy were composed of a less pro-inflammatory population (with reduced IFN-γ and IL-17+ CD4+ T cells), which exhibited a reduced pro-inflammatory response when restimulated in vitro (165, 166). In an autoimmune uveitis model (166), T cells from MSC-treated groups showed reduced proliferative response and produced less pro-inflammatory Th1 and Th17 cytokines, but more anti-inflammatory IL-10, upon antigen restimulation.

Apart from modulating the T cell profile and inflammatory responses, MSC treatment can also induce Tregs in SLOs. In studies of autoimmune disease and allograft transplantation, MSCs inhibited inflammation by inducing an increase in FoxP3+ Tregs in the draining LNs and the spleen (156, 166–169). Similarly, an increase in splenic Tregs after MSC treatment was observed in ischemic kidney injury models. The importance of Treg induction in this model was highlighted when the therapeutic effects of MSCs were abrogated following the depletion of Tregs or the complete excision of the spleen (170).

**Myeloid Cells in SLOs Are a Critical Mediator of MSC Effects**

Studies have established that co-culturing different myeloid cell populations with MSCs induces regulatory phenotypes, which can modulate immune responses. For example, DCs co-cultured with MSCs downregulated their expression of co-stimulatory molecules and were found to be less stimulatory in activating T cell responses in vitro (171–173). Monocytes and macrophages exposed to MSCs were less pro-inflammatory (produced less TNF and IL-12, and more IL-10 and IL-6) (174), more phagocytic and had increased bacterial killing capacity (33, 174–176). Macrophages with an immunoregulatory profile could further maintain an anti-inflammatory microenvironment and influence Treg generation (174, 177). Induction of amphiregulin in MSC-primed macrophages was recently identified as one pathway leading to induction of Tregs and decreased Th1 responses (178). The phenotype and morphology of macrophages ‘re-educated’ by MSCs share some similarities with myeloid-derived suppressor cells (MDSCs), which are differentiated from immature myeloid cells via PGE2 and IL-10-dependent mechanisms, and have immunosuppressive function (177). However, these in vitro findings need to be contextualized within the complex structural organization and cellular composition of the SLOs.
Studies examining immune cell changes in SLOs following MSC therapy support a role for myeloid cells in mediating the immunomodulatory effects of MSCs. When infused in a GvHD model, MSCs overexpressing the homing molecule, ICAM-1, were found in greater numbers in the SLOs (compared to control MSCs) and were found to inhibit splenic DC activation and maturation, suppress CD4+ T cell differentiation, and increase the splenic Treg/effector T cell ratio (159). Whilst it remains to be established that the change in regulatory/effector T cell balance is a direct consequence of DC function altered by MSCs in the spleen, studies have linked the induction of Tregs to CD11b+ phagocytic cells. Co-culture of splenocytes with MSCs induced Tregs, but not in the absence of CD11b+ cells (156). In a model of enterocolitis, the increase in Tregs in the SLOs underlies MSC therapeutic efficacy, which is abrogated upon the depletion of CD11b+ cells by clodronate-filled liposomes (156). Importantly, adoptive transfer of CD11b+ cells that had been co-cultured with MSCs was sufficient to increase Tregs in the SLOs and protect against disease (156). In another study using an osteosarcoma xenograft model in mice lacking T cells, clodronate depletion of CD11b+ splenic macrophages increased the amount of bioluminescence signal of luciferase-expressing MSCs found in the spleen after IV injection, and subsequently facilitated MSC delivery to the tumor (179). The data suggest that MSCs are phagocytosed by macrophages in the spleen, and overcoming this barrier promotes tissue-targeted delivery of MSCs. Thus, while the tolerogenic outcome of efferocytosis can contribute to the anti-inflammatory effects of MSC therapy, settings that require efficient delivery of MSCs to tissues may need to employ strategies that avoid splenic macrophage clearance.

CONCLUSION AND FUTURE DIRECTIONS

MSCs exhibit broad spectrum immunomodulatory effects in various inflammatory diseases, but do not persist for significant periods in any part of the body following IV infusion. Instead, their lung entrapment and rapid clearance has shifted the focus to lung phagocytic cells as mediators of their therapeutic effects. Although traces of MSCs have been found in SLOs, along with changes in immune cell composition and function, limitations in labelling and imaging techniques make it difficult to establish with certainty that the small numbers detected are viable MSCs, cell debris or label redistribution following phagocytic uptake. There are several cell types with phagocytic capacity in the SLOs, including migratory cells from the circulation. Cells found in different compartments of the spleen and LNs perform different function, which depends crucially upon their spatial interactions with other cells and chemical cues. Furthermore, SLOs comprise not just immune cells, but also a variety of stromal populations that have functional roles in health and disease (180, 181), including the capacity to efferocytose apoptotic cells (182). Whether these stromal populations have a role in MSC therapy is an open area to explore.

REFERENCES

1. Rendra E, Scaccia E, Bieback K. Recent Advances in Understanding Mesenchymal Stromal Cells. F1000Res (2020) 9:156. doi: 10.12688/f1000research.28162.1
2. Jossen V, van den Bos C, Eibl R, Eibl D. Manufacturing Human Mesenchymal Stem Cells at Clinical Scale: Process and Regulatory Challenges. Appl Microbiol Biotechnol (2018) 102:3981–94. doi: 10.1007/s00253-018-9265-6
3. Martin I, Galipeau J, Kessler C, Le Blanc K, Dazzi F. Challenges for Mesenchymal Stromal Cell Therapies. Sci Transl Med (2019) 11(480): eaat2189. doi: 10.1126/scitranslmed.aat2189
4. Kabat M, Bobkov I, Kumar S, Grunet M. Trends in Mesenchymal Stem Cell Clinical Trials 2004-2018: Is Efficacy Optimal in a Narrow Dose Range? Stem Cells Transl Med (2020) 9:17–27. doi: 10.1002/sctm.19-0202

AUTHOR CONTRIBUTIONS

DZ, TB, NP, and TH contributed conception and design of the manuscript. DZ wrote the first draft of the manuscript and made the figures. TB, NP, and TH wrote sections of the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.

FUNDING

DZ and TB are recipients of the Australian Government Research Training Program (RTP) Scholarship. TH is supported by funding from the National Health and Medical Research Council of Australia (GNT1101788, GNT1162499, GNT2012290) and the Australian Research Council (IC190100026). The Australian Regenerative Medicine Institute is supported by grants from the State Government of Victoria and the Australian Government.

ACKNOWLEDGMENTS

The authors thank Ivan Poon and Scott Mueller for helpful discussion.

5. Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-Based Product Characterization for Clinical Trials: An FDA Perspective. Cell Stem Cell (2014) 14:141–5. doi: 10.1016/j.stem.2014.01.013
6. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal Criteria for Defining Multipotent Mesenchymal Stromal Cells. The International Society for Cellular Therapy Position Statement. Cytotherapy (2006) 8:315–7. doi: 10.1080/14653240600859905
7. Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L. Therapy MSCs: The International Society for Cellular Therapy (ISCT) Working Group Proposal. Cytotherapy (2013) 15:1054–61. doi: 10.1016/j.jcyt.2013.02.010
8. Bianco P, Cao X, Frenette PS, Mao JJ, Robey PG, Simmons PJ, et al. The Meaning, the Sense and the Significance: Translating the Science of Mesenchymal Stem Cells Into Medicine. Nat Med (2013) 19:35–42. doi: 10.1038/nm.3028
9. Robey P. "Mesenchymal Stem Cells": Fact or Fiction, and Implications in Their Therapeutic Use. *F1000Res* (2017) 6:524. doi: 10.12688/f1000research.10955.1
10. Cherian DS, Bhuvan T, Meagher L, Heng TSP. Biological Considerations in Scaling Up Therapeutic Cell Manufacturing. *Front Pharmacol* (2020) 11:654. doi: 10.3389/fphar.2020.00654
11. Cottle C, Porter AP, Lipat A, Turner-Lyles C, Nguyen J, Moll G, et al. Impact of Cryopreservation and Freeze-Thawing on Therapeutic Properties of Mesenchymal Stromal/Stem Cells and Other Common Cellular Therapeutics. *Curr Stem Cell Rep* (2022) 8:72–92. doi: 10.1007/s40778-022-00212-1
12. Moll G, Ankrum JA, Olson SD, Nolta JA. Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products. *Stem Cells Trans Med* (2017) 1:112–13. doi: 10.1089/stlm/zz3005
13. Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBrujin J, et al. International Society for Cellular Therapy Perspective on Immune Functional Assays for Mesenchymal Stromal Cells as Potency Release Criterion for Advanced Phase Clinical Trials. *Cytotherapy* (2016) 18:151–9. doi: 10.1016/j.jcyt.2015.11.008
14. Moll G, Ankrum JA, Kamhiieh-Milz J, Bieback K, Ringde K, et al. Mesenchymal Stromal Cell Therapeutic Potency is Required for Their Therapeutic Function. *Stem Cells Dev* (2013) 22:2825–35. doi: 10.1089/scd.2013.0193
15. Moll G, Geissler S, Cottle C, Porter AP, Lipat A, Nguyen J, Moll G, et al. Cryopreserved or Fresh Mesenchymal Stromal Cells Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy? *Adv Exp Med Biol* (2016) 951:77–98. doi: 10.1007/978-3-319-45457-3_7
16. Ankrum JA, Ong JF, Karp JM. Mesenchymal Stem Cells: Immune Evasive, Not Immune Privileged. *Nat Biotechnol* (2016) 34:1522–60. doi: 10.1038/nbt.3281
17. Thomi G, Surbek D, Haezler V, Joerger-Messerli M, Schoeberlein A. Are Therapeutic Human Mesenchymal Stromal Cells Compatible With Human Blood? *Stem Cell Med* (2014) 32:252–60. doi: 10.1038/ncmb.2014.1905
18. Kallmeyer K, Andre-Levigne D, Baquie M, Krause KH, Pepper MS, Pittet-Funke L, et al. Fate of Systemically and Locally Administered Adipose-Derived Mesenchymal Cells and Their Effect on Wound Healing. *Stem Cells Trans Med* (2020) 9:131. doi: 10.1002/sctm.19-0091
19. Mathias LJ, Khong SM, Snyropoulis L, Payne NL, Siatskas C, Thorburn AN, et al. Alveolar Macrophages are Critical for the Inhibition of Allergic Asthma by Mesenchymal Stromal Cells. *J Immunol* (2013) 191:5914–24. doi: 10.4049/jimmunol.1300667
20. Lu Y, Zhou Y, Zhang R, Wen L, Wu K, Li Y, et al. Bone Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Recovery Following Spinal Cord Injury via Improvement of the Integrity of the Blood-Spinal Cord Barrier. *Front Neurosci* (2019) 13:209. doi: 10.3389/fnins.2019.00209
21. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PG, Matteucci P, et al. Human Bone Marrow Stromal Cells Suppress T-Lymphocyte Proliferation Induced by Cellular or Non-specific Mitogenic Stimuli. *Blood* (2002) 99:3838–43. doi: 10.1182/blood.v99.10.3838
22. Bartholomew A, Sturgeon C, Siatkasa M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal Stem Cells Suppress Lymphocyte Proliferation In Vitro and Prolong Skin Graft Survival In Vivo. *Exp Hematol* (2002) 30:42–8. doi: 10.1016/s0091-7782(02)00076-3
23. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PG, Matteucci P, et al. Human Bone Marrow Stromal Cells Suppress T-Lymphocyte Proliferation Induced by Cellular or Non-specific Mitogenic Stimuli. *Blood* (2002) 99:3838–43. doi: 10.1182/blood.v99.10.3838
24. Krampera M, Mesenchymal Stromal Cell 'Licensing': A Multistep Process. *Cell Stem Cell* (2019) 10:1228. doi: 10.3389/fimmu.2019.01228
25. Mahrouf-Yorgov M, Auguel L, Da Silva CC, Jourdan M, Rigolet M, Manin S, et al. Mesenchymal Stem Cells Sense Mitochondria Released From Damaged Cells as Danger Signals to Activate Their Rescue Properties. *Cell Death Differ* (2017) 24:1224–38. doi: 10.1038/cdd.2017.51
26. Saas P, Dagiuadu E, Perruche S. Concise Review: Apoptotic Cell-Based Therapies-Rationale, Preclinical Results and Future Clinical Developments. *Stem Cells* (2016) 34:1464–73. doi: 10.1002/stem.2361
27. Zheng et al. SLOs in MSC Therapy
Zheng et al. SLOs in MSC Therapy
Cells in the Spleen. *Blood* (2011) 117:5403–12. doi: 10.1182/blood-2010-11-320028

84. You, J, Myers RC, Freeberg L, Foote J, Kearney JF, Justement LB, et al. Marginal Zone B Cells Regulate Antigen Capture by Marginal Zone Macrophages. *J Immunol* (2011) 186:2172–81. doi: 10.4049/jimmunol.1002106

85. den Haan JM, Mebius RE, Kraal G. Stromal Cells in the Spleen. *Front Immunol* (2012) 3:201. doi: 10.3389/fimmu.2012.00201

86. Schmidt ME, MacDonald IC, Groom AC. Microcirculation in Mouse Spleen (Nonsinus) Studied by Means of Corrosion Casts. *J Morphol* (1985) 186:17–29. doi: 10.1002/jmor.1051860103

87. van Vliet J, Melis M, van Ewijk W. Marginal Zone Macrophages in the Mouse Spleen Identified by a Monoclonal Antibody. Anatomical Correlation With a B Cell Subpopulation. *J Histochem Cytochem* (1985) 33:40–4. doi: 10.1177/33.3.3880783

88. Geijtenbeek TB, Groot PC, Nolte MA, van Vliet SJ, Gangaram-Panday ST, den Haan JM, Mebius RE, Kraal G. Stromal Cells of the Mouse Spleen. *Scand J Immunol* (1985) 32:1002–10. doi: 10.1111/j.1365-3083.1985.tb00873.x

89. Kuja M, Iannacone M. The Role of Lymph Node Sinus Macrophages in Host Defense. *Ann N Y Acad Sci* (2014) 1319:38–46. doi: 10.1111/nyas.12387

90. Junt T, Moesman EA, Iannacone M, Massberg S, Lang PA, Boes M, et al. Subcapsular Sinus Macrophages in Lymph Node Clear Lymph-Borne Viruses and Present Them to Antiviral B Cells. *Nature* (2007) 450:110–4. doi: 10.1038/nature06287

91. Kuka M, Iannacone M. Antigen Transport to the Lymph Nodes and Regulation by Lymph Node Sinus Macrophages. *J Immunol* (2002) 169:1333–46. doi: 10.4049/jimmunol.169.1.1333

92. Fujiyama S, Nakahashi-Oda C, Abe F, Wang Y, Sato K, Shibuya A. Identification and Isolation of Splenic Tissue-Resident Macrophage Sub- Populations by Flow Cytometry. *Int Immunol* (2019) 31:51–6. doi: 10.1093/intimm/dxy064

93. Kleinclauss F, Perruche S, Masson E, de CarvalhoBittencourt M, Biichle S, de Carvalho-Bittencourt M, Biichle S, Khanna KM, Lefrancois L. Geography and Plumbing Control the T Cell Response Generation and Maintenance. *Immunol Rev* (2017) 303:186–98. doi: 10.1111/imr.12641

94. Blank G, Powell D, van Duijnhoven GC, et al. Marginal Zone Macrophages Express a Murine Homologue of DC-SIGN That Captures Blood-Borne Antigens. *J Immunol* (2003) 171:2872–8. doi: 10.4049/jimmunol.171.5.2872

95. Miyake Y, Asano K, Kaise H, Uemura M, Nakayama M, Tanaka M. Critical Role of Macrophages in the Marginal Zone in the Suppression of Immune Responses. *Front Immunol* (2019) 10:347. doi: 10.3389/fimmu.2018.02472
124. Robinette CD, Fraumeni JF Jr. Splenectomy and Subsequent Mortality in Veterans of the 1939–45 War. Lancet (1977) 2:127–9. doi: 10.1016/S0140-6736(05)80095-5

125. Chotivanich K, Udomsangretch R, McGreedy R, Proux S, Newton P, Rolland D, et al. Central Role of the Spleen in Malaria Parasite Clearance. J Infect Dis (2002) 185:1538–41. doi: 10.1086/340213

126. Ghosh D, Stumhofer JS. The Spleen: “Epiphenon” in Malaria Infection and Immunity. J Leukoc Biol (2021) 110:753–69. doi: 10.1002/JLB.1101102-713R

127. Portero-Sainz I, Gómez-García de la Fuente V, Cuesta-Mateos C, Fernández Portero-Sainz I, Gomez-Garcia deSoria V, Cuesta-Mateos C, Fernandez-Guerrero A, Garcia T. The Spleen: Increases the Incidence and Severity of GVHD. Bone Marrow Transplantation (2017) 52:745–52. doi: 10.1038/bmt.2016.342

128. Acedo SC, Gotardo EM, Lacerda JC, de Oliveira CC, de Oliveira Carvalho P, Gamburo A. Perinodal Adipose Tissue and Mesenteric Lymph Node Activation During Reactivated TNBS-Colitis in Rats. Dig Dis Sci (2011) 56:5245–52. doi: 10.1007/s10620-011-1644-8

129. Yakoub-Agha I, Saule P, Depil S, Micol JB, Grutzmacher C, Boulanger-Depil S, Micol JB, Grutzmacher C, Boulanger-Yakoub-Agha I, Saule P, Depil S, Micol JB, Grutzmacher C, Boulanger-Yakoub-Agha I, Saule P, Depil S, Micol JB, Grutzmacher C, Boulanger-Yakoub-Agha I, Saule P, Depil S, Micol JB, Grutzmacher C, Boulanger-Yakoub-Agha I, Saule P, Depil S, Micol JB, Grutzmacher C, Boulanger.

130. Tamoutounour S, Henri S, Lelouard H, de Bovis B, de Haar C, van der Woude CJ, et al. CD64 Distinguishes Macrophages From Dendritic Cells in the Gut and Reveals the Th1-Inducing Role of Mesenteric Lymph Node Macrophages During Colitis. Eur J Immunol (2012) 42:3150–66. doi: 10.1002/eij.201242847

131. Bsat M, Chapuy L, Rubio M, Wassef R, Richard C, Schwenter F, et al. Differential Pathogenic Th1 Profile in Mesenteric Lymph Nodes of Crohn’s Disease and Ulcerative Colitis Patients. Front Immunol (2019) 10:1177. doi: 10.3389/fimmu.2019.01177

132. Clark CL, Price BA, Malcolm P, Lear PA. Wood RF. Graft Versus Host Disease in Small Bowel Transplantation. Br J Surg (1991) 78:1077–9. doi: 10.1002/bjs.1800780915

133. Brouha PC, Perez-Abadia G, Francois CG, Laurentin-Perez LA, Gorantla V, Vossen M, et al. Lymphadenectomy Prior to Rat Hind Limb Allotransplantation Decreases Mortality and Improves Cognitive Function of Rats After Severe Traumatic Brain Injury. J Trauma (2011) 71:141–7. doi: 10.1097/TA.0b013e1181f069c9

134. Neubauer NL, Lurain JR. The Role of Lymphadenectomy in Surgical Staging of Endometrial Cancer. Int J Surg Oncol (2011) 2011:814649. doi: 10.1155/2011/814649

135. Guidiano AE, Jones RC, Berrnan M, Stamm R. Sentinel Lymphadenectomy in Colorectal Cancer. J Clin Oncol (1997) 15:2345–50. doi: 10.1200/JCO.1997.15.6.2345

136. Li M, Li F, Luo C, Shan Y, Zhang L, Qian Z, et al. Immediate Splenectomy Decreases Mortality and Improves Cognitive Function of Rats After Severe Traumatic Brain Injury. J Trauma (2011) 71:141–7. doi: 10.1097/TA.0b013e181f180e67

137. Das M, Leonardo CC, Rangooni S, Pennypacker KR, Mohapatra S, Mohapatra SS. Lateral Fluid Perfusion Injury of the Brain Induces CCL20 Inflammatory Chemokine Expression in Rats. J Neuroinflamm (2011) 8:148. doi: 10.1186/1742-2094-8-148

138. Savas MC, Ozguner M, Ozguner IF, Delibas N. Splenectomy Attenuates Intestinal Ileitis-Reperfusion-Induced Acute Lung Injury. J Pediatr Surg (2003) 38:1465–70. doi: 10.1016/S0022-3468(03)00497-4

139. Okauchi Y, Miyazaki H, Zeniya M, Ishikawa T, Okhawa Y, Tsudo S, et al. Splenectomy-Reduced Hepatitis Injury Induced by Ischemia/Reperfusion in the Rat. Liver (1996) 16:188–94. doi: 10.1111/j.1600-0676.1996.tb0726x7

140. Seifert HA, Leonardo CC, Hall AA, Rowe DD, Collier LA, Benkovic SA, et al. The Spleen Contributes to Induced Neurodegeneration Through Interferon Gamma Signaling. Metab Brain Dis (2012) 27:131–41. doi: 10.1007/s11011-012-9283-0

141. Chiu NL, Kaiser B, Nguyen YV, Welbourne S, Lall C, Cramer SC. The Volume of the Spleen and Its Correlates After Acute Stroke. J Stroke Cerebrovas Dis (2016) 26:2948–56. doi: 10.1016/j.jstrokecerebrovasdis.2016.08.012

142. Ajmo CTif, Vernon DO, Collier L, Hall AA, Garbuza-ova-Davis S, Willing A, et al. The Spleen Contributed to Induced Neurodegeneration. J Neurosci (2008) 86:2227–34. doi: 10.1002/jnr.21661
Inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy. Circ Res (2017) 120:1598–613. doi: 10.1161/CIRCRESAHA.117.310599

161. Lopez-Santalla M, Mancheno-Corvo P, Escolano A, Menta R, DelaRosa O, Abad JL, et al. Biodistribution and Efficacy of Human Adipose-Derived Mesenchymal Stem Cells Following Intranasal Administration in Experimental Colitis. Front Immunol (2017) 8:638. doi: 10.3389/fimmu.2017.00638

162. Krueger TEG, Thorek DLJ, Denneade SR, Isaacs JT, Brennen WN. Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med (2018) 7:651–63. doi: 10.1002/sctm.18-0024

163. von Bahr L, Batisi I, Moll G, Hagg M, Szakos A, Sundberg B, et al. Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicates Limited Long-Term Engraftment and No Ectopic Tissue Formation. Stem Cells (2012) 30:1575–8. doi: 10.1002/stem.1118

164. Moll G, Jitschin R, von Bahr L, Rasmusson-Duprez I, Sundberg B, Lönnies L, et al. Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses. PLoS One (2011) 6:e21703. doi: 10.1371/journal.pone.0021703

165. Golden JE, Shahaduzzaman M, Wabnitz A, Green S, Womble TA, Sanberg PR, et al. Human Umbilical Cord Blood Cells Alter Blood and Spleen Cell Populations After Stroke. Stroke Transl Res (2012) 3:491–9. doi: 10.1007/s12975-012-0208-3

166. Moll G, Jitschin R, von Bahr L, Rasmusson-Duprez I, Sundberg B, Lönnies L, et al. Mesenchymal Stromal Cells Precondition Lung Monocytes/Macrophages to Produce Tolerance Against Allo- and Autoimmunity in the Eye. Proc Natl Acad Sci U.S.A. (2016) 113:158–63. doi: 10.1073/pnas.1522905113

167. Mancheno-Corvo P, Lopez-Santalla M, Menta R, DelaRosa O, Mulero F, Del Rio B, et al. Intralymphatic Administration of Adipose Mesenchymal Stem Cells Reduces the Severity of Collagen-Induced Experimental Arthritis. Front Immunol (2017) 8:462. doi: 10.3389/fimmu.2017.00462

168. Murphy N, Treacy O, Lynch K, McQueen C, O’Sullivan C, Howard L, et al. TNF-α- and IL-1β-Licensed Mesenchymal Stromal Cells Promote Corneal Allograft Survival via Myeloid Cell-Mediated Induction of FoXP3+ Regulatory T Cells in the Lung. FASEB J (2019) 33:9404–21. doi: 10.1096/fj.201900474R

169. Hu J, Zhang L, Wang N, Ding R, Cui S, Zhu F, et al. Mesenchymal Stem Cells Attenuate Ischemic Acute Kidney Injury by Inducing Regulatory T Cells Through Splenocyte Interactions. Kidney Int (2013) 84:521–31. doi: 10.1038/ki.2013.114

170. Zhang Y, Ge XH, Guo XJ, Guan SB, Li XM, Gu WC, et al. Bone Marrow Mesenchymal Stem Cells Inhibit the Function of Dendritic Cells by Secreting Galectin-1. BioMed Res Int (2017) 2017:3248605. doi: 10.1155/2017/3248605

171. Jiang XZ, Zhang Y, Liu B, Zhang SX, Wu Y, Xu XD, et al. Human Mesenchymal Stem Cells Inhibit Differentiation and Function of Monocyte-Derived Dendritic Cells. Blood (2005) 105:4120–6. doi: 10.1182/blood-2004-02-0586

172. Aldimucci A, Rizzetto L, Pieri L, Nosì D, Romagnoli P, Biagioli T, et al. Inhibition of Immune Synapse by Altered Dendritic Cell Actin Distribution: A New Pathway of Mesenchymal Stem Cell Immune Regulation. J Immunol (2010) 185:5102–10. doi: 10.4049/jimmunol.1001332

173. Kim J, Hematti P. Mesenchymal Stem Cell-Educated Macrophages: A Novel Type of Alternatively Activated Macrophages. Exp Hematol (2009) 37:1445–53. doi: 10.1016/j.exphem.2009.09.004

174. Rabani R, Volchuk A, Jerkic M, Ormershel L, Garces-Ramirez L, Canton J, et al. Mesenchymal Stem Cells Enhance NOX2-Dependent Reactive Oxygen Species Production and Bacterial Killing in Macrophages During Sepsis. Eur Respir J (2018) 51(4):1702021. doi: 10.1183/13993003.02021-2017

175. Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazza IM, Nepomnaschy I, et al. Mouse Bone Marrow-Derived Mesenchymal Stromal Cells Turn Activated Macrophages Into a Regulatory-Like Profile. PLoS One (2010) 5:e9252. doi: 10.1371/journal.pone.0009252

176. Eggenhofer E, Hoogduijn MJ, Mesenchymal Stem Cell-Educated Macrophages. Transplant Res (2012) 1:12. doi: 10.1186/2047-1440-1-12

177. Ko JH, Kim HJ, Jeong HJ, Lee HJ, Oh YJ. Mesenchymal Stem and Stromal Cells Harness Macrophage-Derived Amphiregulin to Maintain Tissue Homeostasis. Cell Rep (2020) 30(11):3806–20.e6. doi: 10.1016/j.celrep.2020.02.062

178. Hasgur S, Desbourdes L, Relation T, Overholt KM, Stanek IR, Guess AJ, et al. Splenic Macrophage Phagocytosis of Intravenously Infused Mesenchymal Stem Cells Attenuates Tumor Localization. Cytotherapy (2021) 23:411–22. doi: 10.1016/j.jcyt.2020.04.102

179. Fletcher AL, Heng TS. Lymph Node Stroma Join the Cancer Support Network. Cell Death Differ (2016) 23:1899–901. doi: 10.1038/cdd.2016.103

180. Fletcher AL, Elman JS, Astariya J, Murray R, Saedii N, D’Rozario I. Lymph Node Fibroblastic Reticular Cell Transplants Show Robust Therapeutic Efficacy in High-Mortality Murine Sepsis. Sci Transl Med (2014) 6:249ra109. doi: 10.1126/scitranslmed.3009377

181. Sato K, Honda SI, Shibuya A, Shibuya K. Cutting Edge: Identification of Marginal Reticular Cells as Phagocytes of Apoptotic B Cells in Germinal Centers. J Immunol (2018) 200:3691–6. doi: 10.4049/jimmunol.1701293

Conflict of Interest: TSPH received funding from Regeneus Ltd outside of this work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zheng, Bhuvan, Payne and Heng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.